Matches in Wikidata for { <http://www.wikidata.org/entity/Q67126100> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q67126100 description "clinical trial" @default.
- Q67126100 description "ensayu clínicu" @default.
- Q67126100 description "klinisch onderzoek" @default.
- Q67126100 description "клінічне випробування" @default.
- Q67126100 name "A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer" @default.
- Q67126100 name "A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer" @default.
- Q67126100 type Item @default.
- Q67126100 label "A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer" @default.
- Q67126100 label "A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer" @default.
- Q67126100 prefLabel "A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer" @default.
- Q67126100 prefLabel "A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer" @default.
- Q67126100 P1132 Q67126100-7EB9BA30-3935-49C1-9227-0E27DF8B8E33 @default.
- Q67126100 P1476 Q67126100-8FEFF885-6A82-4FDA-9A8E-CBA504EB383E @default.
- Q67126100 P17 Q67126100-48F8A551-4A59-429F-9EBC-29AA0649AC13 @default.
- Q67126100 P17 Q67126100-67C58410-9A76-4B9B-987E-E1E7C9A07851 @default.
- Q67126100 P2899 Q67126100-32AD69E0-EB7A-4F66-AA63-B9233BD6B6E8 @default.
- Q67126100 P3098 Q67126100-563C874A-0C97-4DBF-91B4-616BACA40EDE @default.
- Q67126100 P31 Q67126100-371A4B8B-1BE2-4DED-B477-91BD57C4FE80 @default.
- Q67126100 P4135 Q67126100-23C544E3-BCD7-41F2-8A4A-D54B1165B371 @default.
- Q67126100 P4844 Q67126100-2A782560-2B1E-44F3-A4EE-497905ED2FFE @default.
- Q67126100 P4844 Q67126100-D8AC7E5B-ADCE-4159-A73F-32A2C321CBBB @default.
- Q67126100 P580 Q67126100-7D6FA1B8-D5FA-4180-9499-EDF86EDC6636 @default.
- Q67126100 P582 Q67126100-79E19696-BA5C-4CF6-BCB9-C84A631CA7F5 @default.
- Q67126100 P6099 Q67126100-39BF286C-D4A2-4B0B-8ECF-F5650843D637 @default.
- Q67126100 P8363 Q67126100-29B023BD-FD90-4E64-B400-30C2A6CD4071 @default.
- Q67126100 P1132 "+15" @default.
- Q67126100 P1476 "A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin: Part A: Dose Escalation of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer; Followed by Part B: an Expansion Phase of Olaparib in Combination With Carboplatin in the Neoadjuvant Treatment of HER-2 Negative Breast Cancer Patients With Germline BRCA1/2 Mutations" @default.
- Q67126100 P17 Q29 @default.
- Q67126100 P17 Q30 @default.
- Q67126100 P2899 "+18" @default.
- Q67126100 P3098 "NCT02561832" @default.
- Q67126100 P31 Q30612 @default.
- Q67126100 P4135 "+130" @default.
- Q67126100 P4844 Q408524 @default.
- Q67126100 P4844 Q415588 @default.
- Q67126100 P580 "2015-11-06T00:00:00Z" @default.
- Q67126100 P582 "2016-09-30T00:00:00Z" @default.
- Q67126100 P6099 Q5452194 @default.
- Q67126100 P8363 Q78089383 @default.